• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Stents

Huh? Federal courts upholds Boston Scientific’s patent claims against Johnson & Johnson — and vice versa

March 31, 2009 By MassDevice staff Leave a Comment

A federal appeals court ruled that Boston Scientific Corp. and Johnson & Johnson each infringed cardiac stent patents held by the other company, the Wall Street Journal reported.

The outcome of the 10-year court battle is still murky, despite the ruling, which failed to determine “the question of who owes what to whom,” according to the journal.

Filed Under: Business/Financial News, Drug-Eluting Stents

Abbott Labs adds another scalp to its belt in stent war with Boston Scientific

March 31, 2009 By MassDevice staff Leave a Comment

A three-year trial comparing Abbott Laboratories‘ Xience V drug-eluting stent against its Taxus competitor from Boston Scientific Corp. showed that the Abbott device is much more effective three years after implantation.

The news, announced at an American College of Cardiology conference in Orlando, sent the Natick device goliath’s stock into a slight swoon. The Xience product is already outselling the Taxus, and the news promises to accelerate that trend.

Filed Under: Business/Financial News, Drug-Eluting Stents

Boston Scientific gets another credit rating upgrade

March 25, 2009 By MassDevice staff Leave a Comment

The good news: Another credit agency raised Boston Scientific Corp.‘s rating. The bad news: The Natick-based medical devices giant is still rated as a junk bond.

Filed Under: Business/Financial News, Drug-Eluting Stents, Stents Tagged With: Cardiac Rhythm Management

Boston Scientific faces a class-action suit and settles a patent case, only to get slapped with another

March 20, 2009 By MassDevice staff Leave a Comment

March 16 capped off a rough week for Boston Scientific Corp. and its Taxus stent line.

The Natick-based device giant found out March 14 that it faces a class-action lawsuit over the 2004 recall of its Taxus stent.

Two days later, the same day the Natick-based device giant settled a patent infringement case filed by a Texas physician, it was slapped with another by a Hong Kong cardiovascular device maker.

Filed Under: Business/Financial News, Drug-Eluting Stents

Boston Scientific co-founders unload millions in BoSci stock

March 19, 2009 By MassDevice staff Leave a Comment

Boston Scientific Corp. co-founders John Abele and Peter Nicholas unloaded millions of dollars worth of their stakes in the company in March alone.

It’s part of their effort to salvage the Natick-based medical device leviathan’s stock price, which fell from about $45 per share five years ago to less than $9, according to The Boston Globe.

Add to that the failure of its Taxus Express drug-eluting stent and the disastrous, $27 billion buyout Guidant Corp. (which added $10 billion in debt and thousands of safety recalls in 2006).

Filed Under: Business/Financial News, Drug-Eluting Stents, Stents

Boston Scientific launches new imaging catheter, preps for European debut of two stents

March 19, 2009 By MassDevice staff Leave a Comment

Boston Scientific Corp.’s iCross coronary imaging catheter hit the United States market March 19, two days after the company said two of its new drug coated stents should debut in Europe later this year — possibly earlier in non-EU countries.

The Natick medical device colossus said its iCross coronary imaging catheter, designed for use with its intravascular ultrasound iLab imaging system, is now available in the U.S.

Filed Under: Business/Financial News, Catheters, Drug-Eluting Stents

Boston Scientific brass get raises after off year

March 18, 2009 By MassDevice staff Leave a Comment

The board of directors at Boston Scientific Corp. gave themselves a 25 percent pay raise and handed out bonuses to top-level executives — including $16.6 million worth of stock to CEO James Tobin — after a year that saw the company’s stock price drop by nearly a third of its value.

Filed Under: Business/Financial News, Catheters, Drug-Eluting Stents

J. Raymond Elliot leaves Boston Scientific board for private venture

March 13, 2009 By MassDevice staff Leave a Comment

Following a less than two-year stint on the board of directors at Boston Scientific Corp., J. Raymond Elliot resigned his seat to start a new, as-yet unspecified venture.

The Natick medical device colossus said March 9 that Elliot would not stand for re-election at the company’s annual shareholders meeting.

Filed Under: Business/Financial News, Drug-Eluting Stents, Stents

Moody’s upgrades Boston Scientific, but there’s still a ways to go

March 10, 2009 By MassDevice staff Leave a Comment

Out of the frying pan and into … the skillet?

That’s about the size of it for Boston Scientific Corp., which saw its bond rating raised from negative to stable by Moody’s Investors Service. It’s good news, but there’s still a ways to go.

Moody’s upgraded the Natick-based medical device giant’s U.S. public bond rating March 10 from “Ba2” to “Ba1” and its liquidity rating from “SGL-3” to “SGL-2”, while affirming its corporate credit rating at “Ba1.”

Filed Under: Business/Financial News, Drug-Eluting Stents

Boston Scientific’s Taxus stent clears Japanese regulatory approval

March 3, 2009 By MassDevice staff Leave a Comment

Boston Scientific Corp.‘s Taxus Liberte drug-eluting stent was given regulatory approvals in Japan, clearing the way for its appearance on the Japanese market.

The Natick medical device leviathan said March 3 that its paclitaxel-eluting coronary stent system was approved Jan. 28 by Japan’s Ministry of Health, Labor and Welfare. Reimbursement was granted March 2 by the country’s National Health Insurance System.

About 1,300 medical centers perform cardiac catheterizations in Japan, implanting an estimated 200,000 coronary stents annually, according to Boston Scientific.

Filed Under: Business/Financial News, Drug-Eluting Stents

CorNova integrates fiberoptics into stents

March 2, 2009 By MassDevice staff

CorNova Inc. is hoping to take stents to a new level by integrating fiberoptic technology into existing balloon catheter design.

The Burlington medical device manufacturer is developing balloon catheters designed to measure blood vessels from within the balloon during procedures, with an eye toward reducing incidences of stent restenosis (thrombosis), Mass High Tech reported.

Filed Under: Business/Financial News, Stents Tagged With: Technologies

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 65
  • Go to page 66
  • Go to page 67
  • Go to page 68
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS